Sign In
Buy STOK
$28.86
-1.18 (-3.93%)
At Close: Jul 31, 2026
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Thursday, 16'th Apr 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
04:01pm, Wednesday, 08'th Apr 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
04:01pm, Tuesday, 07'th Apr 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
08:32pm, Friday, 27'th Mar 2026
The chair of Stoke Therapeutics disclosed selling 4,355 shares for roughly $174,000 at around $40.00 per share on March 10, 2026. The sale represented 12.20% of Tzianabos' direct Common Stock holdings
Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK
03:07am, Thursday, 26'th Mar 2026
Assenagon Asset Management S.A. boosted its holdings in Stoke Therapeutics, Inc. (NASDAQ: STOK) by 36.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
12:35pm, Tuesday, 24'th Mar 2026
The chief medical officer of Stoke Therapeutics disposed of 14,311 Common Stock shares for a transaction value of $457,000 across three days ending March 19, 2026. This sale represented 26.01% of Tich
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
05:12pm, Tuesday, 17'th Mar 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics (NASDAQ:STOK) Trading Down 6.6% After Insider Selling
01:30am, Saturday, 14'th Mar 2026
Stoke Therapeutics, Inc. (NASDAQ: STOK - Get Free Report)'s share price was down 6.6% during mid-day trading on Friday following insider selling activity. The stock traded as low as $34.69 and last tr
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
05:06pm, Wednesday, 04'th Mar 2026
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
04:01pm, Tuesday, 24'th Feb 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
45,205 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Principal Financial Group Inc.
03:32am, Thursday, 19'th Feb 2026
Principal Financial Group Inc. bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) in the third quarter, according to its most recent 13F filing with the Securities and Exchange
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Wednesday, 18'th Feb 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today
Penserra Capital Management LLC Acquires New Position in Stoke Therapeutics, Inc. $STOK
04:49am, Friday, 06'th Feb 2026
Penserra Capital Management LLC bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) during the undefined quarter, according to its most recent disclosure with the SEC. The insti
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
04:01pm, Wednesday, 04'th Feb 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
